江苏康为世纪生物科技股份有限公司2025年度业绩快报公告

Financial Performance Summary - The company achieved operating revenue of 193.05 million yuan, representing a year-on-year increase of 53.36% [3] - The total profit was -107.32 million yuan, with a net profit attributable to the parent company of -103.28 million yuan, and a net profit excluding non-recurring gains and losses of -134.82 million yuan, all showing a reduction in losses compared to the previous year [3] - The total assets at the end of the reporting period were 1.51 billion yuan, a decrease of 6.65% from the beginning of the period, while the equity attributable to the parent company was 1.36 billion yuan, down 7.54% [4] Business Operations and Factors Influencing Performance - The company focused on consolidating existing businesses while actively exploring new ones, with rapid growth in technology service businesses such as gene sequencing and gene synthesis driving revenue growth [5] - The company improved operational efficiency, controlling expenses effectively despite significant revenue growth, and reduced R&D expenses by optimizing resource allocation and focusing on advantageous projects [5] Changes in Key Financial Metrics - The company experienced a significant reduction in operating profit and total profit compared to the previous year, primarily due to increased revenue from new technology services and effective expense management [6]